CUREVAC NV (5CV.DE) Stock Fundamental Analysis
Europe - FRA:5CV - NL0015436031 - Common Stock
4.612 EUR
0 (-0.04%)
Taking everything into account, 5CV scores 6 out of 10 in our fundamental rating. 5CV was compared to 73 industry peers in the Biotechnology industry. While 5CV has a great health rating, its profitability is only average at the moment. 5CV is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year 5CV was profitable.
In the past year 5CV had a positive cash flow from operations.
5CV had negative earnings in 4 of the past 5 years.
In multiple years 5CV reported negative operating cash flow during the last 5 years.
1.2 Ratios
5CV has a Return On Assets of 28.11%. This is amongst the best in the industry. 5CV outperforms 94.52% of its industry peers.
Looking at the Return On Equity, with a value of 33.02%, 5CV belongs to the top of the industry, outperforming 94.52% of the companies in the same industry.
With an excellent Return On Invested Capital value of 28.35%, 5CV belongs to the best of the industry, outperforming 97.26% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.11% | ||
| ROE | 33.02% | ||
| ROIC | 28.35% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of 5CV (37.93%) is better than 90.41% of its industry peers.
Looking at the Operating Margin, with a value of 40.58%, 5CV belongs to the top of the industry, outperforming 94.52% of the companies in the same industry.
5CV has a better Gross Margin (94.81%) than 91.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 40.58% | ||
| PM (TTM) | 37.93% | ||
| GM | 94.81% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so 5CV is creating value.
5CV has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, 5CV has more shares outstanding
The debt/assets ratio for 5CV has been reduced compared to a year ago.
2.2 Solvency
5CV has an Altman-Z score of 9.56. This indicates that 5CV is financially healthy and has little risk of bankruptcy at the moment.
5CV's Altman-Z score of 9.56 is amongst the best of the industry. 5CV outperforms 87.67% of its industry peers.
5CV has a debt to FCF ratio of 0.18. This is a very positive value and a sign of high solvency as it would only need 0.18 years to pay back of all of its debts.
5CV has a better Debt to FCF ratio (0.18) than 95.89% of its industry peers.
5CV has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
5CV has a better Debt to Equity ratio (0.05) than 69.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.18 | ||
| Altman-Z | 9.56 |
ROIC/WACC3.93
WACC7.22%
2.3 Liquidity
A Current Ratio of 6.17 indicates that 5CV has no problem at all paying its short term obligations.
5CV has a Current ratio of 6.17. This is amongst the best in the industry. 5CV outperforms 82.19% of its industry peers.
5CV has a Quick Ratio of 6.16. This indicates that 5CV is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of 5CV (6.16) is better than 84.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.17 | ||
| Quick Ratio | 6.16 |
3. Growth
3.1 Past
5CV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 170.16%, which is quite impressive.
The Revenue has grown by 675.15% in the past year. This is a very strong growth!
Measured over the past years, 5CV shows a very strong growth in Revenue. The Revenue has been growing by 98.42% on average per year.
EPS 1Y (TTM)170.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.75%
Revenue 1Y (TTM)675.15%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-91.38%
3.2 Future
5CV is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -22.50% yearly.
The Revenue is expected to decrease by -11.22% on average over the next years. This is quite bad
EPS Next Y-165.87%
EPS Next 2Y-62.26%
EPS Next 3Y-31.82%
EPS Next 5Y-22.5%
Revenue Next Year-86.8%
Revenue Next 2Y-59.56%
Revenue Next 3Y-30.81%
Revenue Next 5Y-11.22%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 5.30 indicates a rather cheap valuation of 5CV.
Based on the Price/Earnings ratio, 5CV is valued cheaply inside the industry as 95.89% of the companies are valued more expensively.
5CV is valuated cheaply when we compare the Price/Earnings ratio to 27.86, which is the current average of the S&P500 Index.
5CV is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.3 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 5CV is valued cheaper than 94.52% of the companies in the same industry.
94.52% of the companies in the same industry are more expensive than 5CV, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.29 | ||
| EV/EBITDA | 3 |
4.3 Compensation for Growth
5CV has a very decent profitability rating, which may justify a higher PE ratio.
5CV's earnings are expected to decrease with -31.82% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-62.26%
EPS Next 3Y-31.82%
5. Dividend
5.1 Amount
5CV does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:5CV (10/3/2025, 7:00:00 PM)
4.612
0 (-0.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners6.53%
Inst Owner ChangeN/A
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap1.04B
Analysts72.31
Price Target4.19 (-9.15%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-29.18%
Min EPS beat(2)-39.67%
Max EPS beat(2)-18.68%
EPS beat(4)2
Avg EPS beat(4)34.62%
Min EPS beat(4)-39.67%
Max EPS beat(4)161.44%
EPS beat(8)3
Avg EPS beat(8)-1.81%
EPS beat(12)5
Avg EPS beat(12)-8.17%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-91.68%
Min Revenue beat(2)-96.47%
Max Revenue beat(2)-86.88%
Revenue beat(4)2
Avg Revenue beat(4)75.38%
Min Revenue beat(4)-96.47%
Max Revenue beat(4)366.65%
Revenue beat(8)4
Avg Revenue beat(8)53.09%
Revenue beat(12)4
Avg Revenue beat(12)21.18%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.64%
PT rev (3m)-8.42%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)11.05%
Revenue NQ rev (1m)27.85%
Revenue NQ rev (3m)27.85%
Revenue NY rev (1m)-14.05%
Revenue NY rev (3m)-14.05%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.3 | ||
| Fwd PE | N/A | ||
| P/S | 2.03 | ||
| P/FCF | 5.29 | ||
| P/OCF | 5.09 | ||
| P/B | 1.77 | ||
| P/tB | 1.85 | ||
| EV/EBITDA | 3 |
EPS(TTM)0.87
EY18.86%
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)0.87
FCFY18.89%
OCF(TTM)0.91
OCFY19.65%
SpS2.27
BVpS2.6
TBVpS2.49
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.11% | ||
| ROE | 33.02% | ||
| ROCE | 33.37% | ||
| ROIC | 28.35% | ||
| ROICexc | 78.22% | ||
| ROICexgc | 88.03% | ||
| OM | 40.58% | ||
| PM (TTM) | 37.93% | ||
| GM | 94.81% | ||
| FCFM | 38.42% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score9
Asset Turnover0.74
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.18 | ||
| Debt/EBITDA | 0.14 | ||
| Cap/Depr | 44.58% | ||
| Cap/Sales | 1.55% | ||
| Interest Coverage | 91.31 | ||
| Cash Conversion | 90.71% | ||
| Profit Quality | 101.3% | ||
| Current Ratio | 6.17 | ||
| Quick Ratio | 6.16 | ||
| Altman-Z | 9.56 |
F-Score9
WACC7.22%
ROIC/WACC3.93
Cap/Depr(3y)242.45%
Cap/Depr(5y)397%
Cap/Sales(3y)81.47%
Cap/Sales(5y)93.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)170.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.75%
EPS Next Y-165.87%
EPS Next 2Y-62.26%
EPS Next 3Y-31.82%
EPS Next 5Y-22.5%
Revenue 1Y (TTM)675.15%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-91.38%
Revenue Next Year-86.8%
Revenue Next 2Y-59.56%
Revenue Next 3Y-30.81%
Revenue Next 5Y-11.22%
EBIT growth 1Y171.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-152.22%
EBIT Next 3Y-32.99%
EBIT Next 5Y10.78%
FCF growth 1Y160.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y182.06%
OCF growth 3YN/A
OCF growth 5YN/A